Luhua (Michael) Wang
M.D. Anderson Cancer Center
13
13
3
N/A
0
14
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+17 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Shaji Kumar
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Isidro Jarque, MD
Hospital Universitario La Fe
Shared therapeutic areas:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Maria José Ramírez Sánchez, MD
Hospital del SAS Jerez
Shared therapeutic areas:
Secundino Ferrer, MD
Hospital Dr. Peset
Shared therapeutic areas:
Elena Pérez Ceballos, MD
Hospital Morales Meseguer
Shared therapeutic areas:
Antonio Gutiérrez, MD
Hospital Son Espasses
Shared therapeutic areas:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
All 13 trials loaded